| Product Code: ETC13302569 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Daratumumab Market was valued at USD 5.2 Billion in 2024 and is expected to reach USD 7.6 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The global daratumumab market is witnessing significant growth driven by its effectiveness in treating multiple myeloma, a type of blood cancer. Daratumumab, a monoclonal antibody, has shown promising results in clinical trials and has gained regulatory approvals for various indications. The increasing prevalence of multiple myeloma, coupled with the rising investment in research and development activities by key market players, is further propelling market growth. Additionally, the expanding geriatric population, who are more susceptible to multiple myeloma, is contributing to the market expansion. With continuous advancements in treatment options and increasing adoption of daratumumab in combination therapies, the global daratumumab market is expected to continue its growth trajectory in the coming years.
The global daratumumab market is experiencing significant growth due to the increasing prevalence of multiple myeloma and the expanding approval of daratumumab for various indications. Key trends in the market include the rising adoption of daratumumab as a standard of care in multiple myeloma treatment, ongoing clinical trials exploring its efficacy in combination therapies, and the development of subcutaneous formulations for improved patient convenience. Opportunities in the market lie in expanding the use of daratumumab in earlier lines of therapy, exploring its potential in new indications beyond multiple myeloma, and increasing market penetration in emerging economies. Collaborations between pharmaceutical companies for combination therapies and personalized medicine approaches are also expected to drive growth in the global daratumumab market.
In the Global Daratumumab Market, some challenges include the high cost of treatment, which may limit access for patients in certain regions or healthcare systems. Additionally, competition from other emerging therapies in the field of multiple myeloma and potential patent expirations could impact market share. Regulatory hurdles and delays in approvals for new indications or formulations may also pose challenges for manufacturers. Furthermore, the complexity of the treatment regimen and the need for healthcare professionals to have specialized training for administration and management of potential side effects can be barriers to adoption. Overall, navigating these challenges while maintaining a competitive edge in the market will be crucial for companies operating in the Global Daratumumab Market.
The global Daratumumab market is primarily driven by the increasing prevalence of multiple myeloma, a type of blood cancer for which Daratumumab is approved as a treatment. The rising geriatric population, who are more susceptible to developing multiple myeloma, is also contributing to market growth. Additionally, advancements in healthcare infrastructure, growing awareness about available treatment options, and the expanding research and development activities in the field of oncology are further propelling the demand for Daratumumab. Moreover, the drug`s effectiveness in combination therapy regimens and its approval for various stages of multiple myeloma treatment are enhancing its market penetration. Overall, the increasing incidence of multiple myeloma and the continuous efforts to improve treatment outcomes are the key drivers fueling the growth of the global Daratumumab market.
Government policies related to the Global Daratumumab Market may vary by region, but overall, the regulatory landscape plays a crucial role in shaping market dynamics. Regulatory bodies such as the FDA in the United States and the European Medicines Agency in the EU have approved Daratumumab for certain indications, providing market access for the drug. Pricing and reimbursement policies set by government agencies also impact the market, influencing the affordability and availability of Daratumumab for patients. Additionally, intellectual property laws and patent protections enforced by governments can affect market competition and the entry of biosimilar versions of Daratumumab. Overall, government policies play a significant role in governing the development, approval, pricing, and market access of Daratumumab in different regions.
The global daratumumab market is expected to witness significant growth in the coming years, driven by the increasing prevalence of multiple myeloma and other hematological malignancies, as well as the expanding applications of daratumumab in various treatment regimens. The drug`s proven efficacy and safety profile, along with ongoing research and development efforts to explore its potential in other indications, will further fuel market expansion. Additionally, the introduction of biosimilar versions of daratumumab may enhance market competition and accessibility. However, challenges such as high treatment costs and regulatory hurdles in certain regions may hinder market growth to some extent. Overall, with the continuous advancements in healthcare technologies and increasing investments in oncology research, the global daratumumab market is poised for a promising future.
In the global daratumumab market, each region exhibits unique trends and opportunities. Asia is poised for significant growth due to increasing prevalence of multiple myeloma and expanding healthcare infrastructure. North America leads in daratumumab sales, driven by advanced healthcare systems and high adoption rates. Europe follows closely, with a strong emphasis on research and development in oncology. The Middle East and Africa region shows growing interest in innovative treatments like daratumumab, despite challenges in access to care. Latin America presents opportunities for market expansion, fueled by improving healthcare access and rising awareness about multiple myeloma treatments. Overall, the global daratumumab market is dynamic, with each region offering distinct market dynamics and growth potential.
Global Daratumumab Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Daratumumab Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Daratumumab Market Revenues & Volume, 2021 & 2031F |
3.3 Global Daratumumab Market - Industry Life Cycle |
3.4 Global Daratumumab Market - Porter's Five Forces |
3.5 Global Daratumumab Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Daratumumab Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Global Daratumumab Market Revenues & Volume Share, By Technology Type, 2021 & 2031F |
3.8 Global Daratumumab Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Global Daratumumab Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Global Daratumumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Daratumumab Market Trends |
6 Global Daratumumab Market, 2021 - 2031 |
6.1 Global Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Daratumumab Market, Revenues & Volume, By Injectable Daratumumab, 2021 - 2031 |
6.1.3 Global Daratumumab Market, Revenues & Volume, By Daratumumab Biosimilar, 2021 - 2031 |
6.1.4 Global Daratumumab Market, Revenues & Volume, By Combination Therapy, 2021 - 2031 |
6.1.5 Global Daratumumab Market, Revenues & Volume, By Oral Daratumumab, 2021 - 2031 |
6.2 Global Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Daratumumab Market, Revenues & Volume, By Monoclonal Antibody, 2021 - 2031 |
6.2.3 Global Daratumumab Market, Revenues & Volume, By Biosimilar Technology, 2021 - 2031 |
6.2.4 Global Daratumumab Market, Revenues & Volume, By Immunotherapy, 2021 - 2031 |
6.2.5 Global Daratumumab Market, Revenues & Volume, By Oral Drug Delivery, 2021 - 2031 |
6.3 Global Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Daratumumab Market, Revenues & Volume, By Oncologists, 2021 - 2031 |
6.3.3 Global Daratumumab Market, Revenues & Volume, By Healthcare Providers, 2021 - 2031 |
6.3.4 Global Daratumumab Market, Revenues & Volume, By Cancer Patients, 2021 - 2031 |
6.3.5 Global Daratumumab Market, Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031 |
6.4 Global Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Daratumumab Market, Revenues & Volume, By Multiple Myeloma Treatment, 2021 - 2031 |
6.4.3 Global Daratumumab Market, Revenues & Volume, By Cancer Therapy, 2021 - 2031 |
6.4.4 Global Daratumumab Market, Revenues & Volume, By Co-Therapy with Chemotherapy, 2021 - 2031 |
6.4.5 Global Daratumumab Market, Revenues & Volume, By Advanced Myeloma Care, 2021 - 2031 |
7 North America Daratumumab Market, Overview & Analysis |
7.1 North America Daratumumab Market Revenues & Volume, 2021 - 2031 |
7.2 North America Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Daratumumab Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Daratumumab Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Daratumumab Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.4 North America Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
7.5 North America Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6 North America Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
8 Latin America (LATAM) Daratumumab Market, Overview & Analysis |
8.1 Latin America (LATAM) Daratumumab Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Daratumumab Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Daratumumab Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Daratumumab Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Daratumumab Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.4 Latin America (LATAM) Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
8.5 Latin America (LATAM) Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
8.6 Latin America (LATAM) Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
9 Asia Daratumumab Market, Overview & Analysis |
9.1 Asia Daratumumab Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Daratumumab Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Daratumumab Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Daratumumab Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Daratumumab Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.4 Asia Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
9.5 Asia Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
9.6 Asia Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
10 Africa Daratumumab Market, Overview & Analysis |
10.1 Africa Daratumumab Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Daratumumab Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Daratumumab Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Daratumumab Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Daratumumab Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.4 Africa Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
10.5 Africa Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
10.6 Africa Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
11 Europe Daratumumab Market, Overview & Analysis |
11.1 Europe Daratumumab Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Daratumumab Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Daratumumab Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Daratumumab Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Daratumumab Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.4 Europe Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
11.5 Europe Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
11.6 Europe Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
12 Middle East Daratumumab Market, Overview & Analysis |
12.1 Middle East Daratumumab Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Daratumumab Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Daratumumab Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Daratumumab Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Daratumumab Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Daratumumab Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.4 Middle East Daratumumab Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
12.5 Middle East Daratumumab Market, Revenues & Volume, By End User, 2021 - 2031 |
12.6 Middle East Daratumumab Market, Revenues & Volume, By Application, 2021 - 2031 |
13 Global Daratumumab Market Key Performance Indicators |
14 Global Daratumumab Market - Export/Import By Countries Assessment |
15 Global Daratumumab Market - Opportunity Assessment |
15.1 Global Daratumumab Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Daratumumab Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.3 Global Daratumumab Market Opportunity Assessment, By Technology Type, 2021 & 2031F |
15.4 Global Daratumumab Market Opportunity Assessment, By End User, 2021 & 2031F |
15.5 Global Daratumumab Market Opportunity Assessment, By Application, 2021 & 2031F |
16 Global Daratumumab Market - Competitive Landscape |
16.1 Global Daratumumab Market Revenue Share, By Companies, 2024 |
16.2 Global Daratumumab Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here